About anaptysbio inc - ANAB
AnaptysBio, Inc. is a clinical stage biotechnology company. engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers SHM platform that replicate the natural process of somatic hypermutation embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.
ANAB At a Glance
AnaptysBio, Inc.
10770 Wateridge Circle
San Diego, California 92121-5801
| Phone | 1-858-362-6295 | Revenue | 234.60M | |
| Industry | Biotechnology | Net Income | -13,232,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 157.015% | |
| Fiscal Year-end | 12 / 2026 | Employees | 104 | |
| View SEC Filings |
ANAB Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 5.943 |
| Price to Book Ratio | 36.505 |
| Price to Cash Flow Ratio | 70.78 |
| Enterprise Value to EBITDA | 27.29 |
| Enterprise Value to Sales | 5.853 |
| Total Debt to Enterprise Value | 0.212 |
ANAB Efficiency
| Revenue/Employee | 2,255,798.077 |
| Income Per Employee | -127,230.769 |
| Receivables Turnover | 6.931 |
| Total Asset Turnover | 0.553 |
ANAB Liquidity
| Current Ratio | 9.068 |
| Quick Ratio | 9.068 |
| Cash Ratio | 8.068 |
ANAB Profitability
| Gross Margin | 98.967 |
| Operating Margin | 20.416 |
| Pretax Margin | -5.57 |
| Net Margin | -5.64 |
| Return on Assets | -3.12 |
| Return on Equity | -24.486 |
| Return on Total Capital | -4.036 |
| Return on Invested Capital | -3.463 |
ANAB Capital Structure
| Total Debt to Total Equity | 781.08 |
| Total Debt to Total Capital | 88.65 |
| Total Debt to Total Assets | 79.76 |
| Long-Term Debt to Equity | 775.49 |
| Long-Term Debt to Total Capital | 88.016 |